- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/605 - Glucagons
Patent holdings for IPC class C07K 14/605
Total number of patents in this class: 1502
10-year publication summary
|
97
|
113
|
90
|
134
|
138
|
136
|
166
|
131
|
141
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2278 |
111 |
| Hanmi Pharm. Co., Ltd. | 552 |
80 |
| Zealand Pharma A/S | 241 |
78 |
| Eli Lilly and Company | 3715 |
69 |
| Sanofi | 3935 |
47 |
| Indiana University Research and Technology Corporation | 801 |
20 |
| Takeda Pharmaceutical Company Limited | 2945 |
18 |
| Merck Sharp & Dohme LLC | 3744 |
18 |
| Sun Pharmaceutical Industries Limited | 759 |
17 |
| Hanmi Science Co., Ltd. | 140 |
16 |
| MedImmune Limited | 622 |
16 |
| Intarcia Therapeutics, Inc. | 105 |
15 |
| President and Fellows of Harvard College | 5905 |
14 |
| The Scripps Research Institute | 1352 |
14 |
| Boehringer Ingelheim International GmbH | 4756 |
13 |
| Hybio Pharmaceutical Co., Ltd. | 120 |
13 |
| Duke University | 3008 |
12 |
| Bachem Holding AG | 35 |
12 |
| The Trustees of the University of Pennsylvania | 4255 |
11 |
| Ip2ipo Innovations Limited | 164 |
11 |
| Other owners | 897 |